Supernus Pharmaceuticals 대차 대조표 상태

재무 상태 기준 확인 6/6

Supernus Pharmaceuticals 의 총 주주 지분은 $1.0B 이고 총 부채는 $0.0, 이는 부채 대 자기자본 비율을 0% 로 가져옵니다. 총자산과 총부채는 각각 $1.3B 및 $335.6M 입니다. Supernus Pharmaceuticals 의 EBIT는 $60.8M 이며 이자보상배율은 -4.6 입니다. $403.2M 의 현금 및 단기 투자금을 보유하고 있습니다.

주요 정보

부채 비율

US$0

부채

이자 보상 비율	-4.6x
현금	US$403.21m
주식	US$1.01b
총 부채	US$335.55m
총 자산	US$1.34b

최근 재무 상태 업데이트

We Think Supernus Pharmaceuticals (NASDAQ:SUPN) Can Stay On Top Of Its Debt

May 10

Does Supernus Pharmaceuticals (NASDAQ:SUPN) Have A Healthy Balance Sheet?

Feb 03

These 4 Measures Indicate That Supernus Pharmaceuticals (NASDAQ:SUPN) Is Using Debt Reasonably Well

Oct 19

Recent updates

Supernus Pharmaceuticals: Recently Launched Qelbree Is Powering Growth

Nov 12

Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Share Price Could Signal Some Risk

Oct 31

Supernus: Stock Slides As Qelbree Sales Questioned, But Positives Still Outweigh Negatives

Sep 12

Supernus Pharmaceuticals' (NASDAQ:SUPN) Conservative Accounting Might Explain Soft Earnings

Aug 19

Supernus Pharmaceuticals: So-So Neuroscience Portfolio, With ADHD Standout

Jul 02

Subdued Growth No Barrier To Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Price

Apr 24

These 4 Measures Indicate That Supernus Pharmaceuticals (NASDAQ:SUPN) Is Using Debt Reasonably Well

Oct 19

Supernus stock falls 12.6% after FDA declines to approve Parkinson’s disease treatment

Oct 10

Supernus Pharmaceuticals: Deep Expertise In CNS, Eyes On Qelbree Launch And Parkinson Portfolio

Aug 19

Supernus Pharmaceuticals' (NASDAQ:SUPN) Soft Earnings Are Actually Better Than They Appear

Aug 16

Supernus: A Work In Progress

Jul 29

Supernus: New Beginnings

Mar 28

재무 상태 분석

단기부채: SUPN 의 단기 자산 ( $640.0M )이 단기 부채( $291.5M ).

장기 부채: SUPN 의 단기 자산( $640.0M )이 장기 부채( $44.0M ).

부채 대 자본 내역 및 분석

부채 수준: SUPN 부채가 없습니다.

부채 감소: SUPN 는) 부채 대 자기자본 비율이 65.4% 였던 5년 전과 비교하여 부채가 없습니다.

부채 범위: SUPN 은 부채가 없으므로 영업현금흐름으로 충당할 필요가 없습니다.

이자 보장: SUPN 에는 부채가 없으므로 이자 지불에 대한 보장은 문제가 되지 않습니다.

Supernus Pharmaceuticals 대차 대조표 상태

재무 상태 기준 확인 6/6

주요 정보

최근 재무 상태 업데이트

We Think Supernus Pharmaceuticals (NASDAQ:SUPN) Can Stay On Top Of Its Debt

Does Supernus Pharmaceuticals (NASDAQ:SUPN) Have A Healthy Balance Sheet?

These 4 Measures Indicate That Supernus Pharmaceuticals (NASDAQ:SUPN) Is Using Debt Reasonably Well

Supernus Pharmaceuticals, Inc. announced delayed 10-Q filing

Recent updates

Supernus Pharmaceuticals: Recently Launched Qelbree Is Powering Growth

Supernus Pharmaceuticals, Inc. Increases Earnings Guidance for the Year 2024

Supernus Pharmaceuticals, Inc. Presents Promising Data from Open-Label Phase 2A Study of SPN-820 Data in Major Depressive Disorder At Psych Congress 2024

Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Share Price Could Signal Some Risk

Supernus Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 04, 2024

Supernus Pharmaceuticals, Inc. Announces Data from its Exploratory Open-Label Phase 2a Clinical Study of SPN-820 in Adults with Major Depressive Disorder

Supernus: Stock Slides As Qelbree Sales Questioned, But Positives Still Outweigh Negatives

Supernus Pharmaceuticals' (NASDAQ:SUPN) Conservative Accounting Might Explain Soft Earnings

Supernus Pharmaceuticals, Inc. Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA

Supernus Pharmaceuticals, Inc. Raises Financial Guidance for the Full Year 2024

Supernus Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Supernus Pharmaceuticals: So-So Neuroscience Portfolio, With ADHD Standout

First quarter 2024 earnings released: EPS: US$0.002 (vs US$0.31 in 1Q 2023)

Supernus Pharmaceuticals, Inc. Reiterates Financial Guidance for the Full Year 2024

Supernus Pharmaceuticals, Inc., Annual General Meeting, Jun 14, 2024

Supernus Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 08, 2024

Subdued Growth No Barrier To Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Price

Consensus EPS estimates fall from profit to US$0.01 loss

Insider notifies of intention to sell stock

Consensus EPS estimates increase by 44%, revenue downgraded

Supernus Pharmaceuticals: Moving Through An 'Inflection Year'

Founder exercised options and sold US$469k worth of stock

Supernus Pharmaceuticals, Inc. Announces Intangible Asset Impairment Charges for the Quarter Ended December 31, 2023

Supernus Pharmaceuticals, Inc. Announces Intangible Asset Impairment Charges for the Quarter Ended December 31, 2023

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Supernus Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Insider notifies of intention to sell stock

Consensus EPS estimates upgraded to US$0.06 loss

Founder exercised options and sold US$331k worth of stock

Consensus estimates of losses per share improve by 58%

Investor sentiment improves as stock rises 18%

Supernus Pharmaceuticals, Inc. Revises Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Supernus Pharmaceuticals, Inc. Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA

Consensus EPS estimates fall by 64%

Supernus Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 08, 2023

New minor risk - Insider selling

Consensus EPS estimates fall by 64%

Supernus Pharmaceuticals, Inc. Resubmits NDA for SPN-830 Apomorphine Infusion Device

Supernus Pharmaceuticals, Inc. Announces New Qelbree®? Data Showing Improvement in ADHD Symptoms

Founder exercised options and sold US$539k worth of stock

Insider notifies of intention to sell stock

Supernus Pharmaceuticals, Inc. Appoints Bethany L. Sensenig to Board of Directors

Consensus EPS estimates fall by 40%

New minor risk - Shareholder dilution

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Supernus Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year 2023

Supernus Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Supernus Pharmaceuticals, Inc.(NasdaqGM:SUPN) dropped from Russell 2000 Value-Defensive Index

Consensus estimates of losses per share improve by 84%

Founder exercised options and sold US$547k worth of stock

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Supernus Pharmaceuticals, Inc. Revises Earnings Guidance for the Year 2023

We Think Supernus Pharmaceuticals (NASDAQ:SUPN) Can Stay On Top Of Its Debt

Senior Vice President of Quality recently sold US$172k worth of stock

Consensus EPS estimates fall from profit to US$0.033 loss

Full year 2022 earnings: EPS and revenues miss analyst expectations

Supernus Pharmaceuticals, Inc. to Report Q4, 2022 Results on Feb 28, 2023

Founder exercised options and sold US$446k worth of stock

Does Supernus Pharmaceuticals (NASDAQ:SUPN) Have A Healthy Balance Sheet?

Insider exercised options and sold US$149k worth of stock

Insider notifies of intention to sell stock

Independent Chairman of the Board exercised options to buy US$311k worth of stock.

Founder exercised options and sold US$439k worth of stock

Consensus forecasts updated

Founder exercised options and sold US$343k worth of stock

Insufficient new directors

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Supernus Pharmaceuticals, Inc. Revises Earnings Guidance for the Full Year 2022

Supernus Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 08, 2022

These 4 Measures Indicate That Supernus Pharmaceuticals (NASDAQ:SUPN) Is Using Debt Reasonably Well